1. Белоусова Т.А., Лукашова Н.Н. Дифференцированный подход к выбору наружных глюкокортикостероидов в терапии дерматозов. Клин. дерматол. и венерол. 2006; 3: 74–8.
2. Albrecht G. Clinical comparision of methylprednizolone aceponate and prednicarbate in chronic eczema. J Eur Acad Dermatol Venerol 1994; 3 (Suppl. 1): 42–8.
3. Bieber T et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007; 62: 184–9.
4. Haneke E. The treatment of atopic dermatitis with methylprednizolone aceponate (MPA), a new topical corticosteroid. J Dermatol Treat 1992; 3 (Suppl. 2): 13–5.
5. Luger TA. Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer index. Leitlinie der Deutschen Dermatologischen Gesellschaft 2004; 7: 629–34.
6. Mori M, Pimpinelli N, Gianotti B. Topical corticosteroids and unwanted local effects: improving the benefit/risk ratio. Drug Safety 1994; 10: 5: 406–12.
7. Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders – a clinical update. Int J Clin Pract 2006; 60 (1): 85–92.
8. Zaumseil RP, Fuhrman H et al. Methylprednisolone aceponate (Ad-vantan) – an effective topical corticoid therapy with few side effects. J Dermatol 1992; 3: 247–63.